RxDoctor Payments Data

Bozena Wolanska, MD

Internal Medicine · Fredericksburg, VANPI 1689660839

Payments from drug & device makers

$8,711in general payments, 2019–2025

Across 648 payments — averaging $13.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$763
  • AstraZeneca$716
  • Lilly USA, LLC$567
  • Pfizer$561
  • Novartis$547
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$8,59499%
  • Education$1161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,711 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$374,375
Medicare patients
890
Services billed
4,993

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$184,861
EliquisApixaban77$83,112
JanuviaSitagliptin Phosphate51$54,276
FarxigaDapagliflozin Propanediol38$51,237
XareltoRivaroxaban28$31,899
JardianceEmpagliflozin18$21,748
Atorvastatin Calcium706$6,808
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$6,328
Valsartan180$6,198
Levothyroxine Sodium407$5,604
Rosuvastatin Calcium321$4,983
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$4,409
SynthroidLevothyroxine Sodium53$3,471
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide91$3,351
Venlafaxine Hcl ErVenlafaxine Hcl36$3,178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$763$184,86182 claims
PfizerEliquis$561$83,11277 claims
MerckJanuvia$221$54,27651 claims
AstraZenecaFarxiga$716$51,23738 claims
Johnson & JohnsonXarelto$50$31,89928 claims
Boehringer IngelheimJardiance$69$21,74818 claims
AbbVieSynthroid$1,086$3,47153 claims
Scilex Pharmaceuticals Inc.Colchicine$17$1,55622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Fredericksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →